Table 3.
Clinical characteristics and outcomes of patients with calciphylaxis treated with sodium thiosulfate relative to those who did not (derived from cohort studies)
| Sodium thiosulfate | No. of studies | No. of patients | Weighted mean difference (95% CI) | P | I2 index, % | Q-test P value | Egger’s test P value |
|---|---|---|---|---|---|---|---|
| Age, yr | 4 | 129 | −0.16 (−5.43 to 5.11) | 0.95 | 0 | 0.90 | 0.77 |
| Dialysis vintage, yr | 3 | 28 | −0.52 (−1.76 to 0.72) | 0.16 | 0 | 0.77 | 0.58 |
| Serum calcium, mg/dl | 3 | 28 | −0.01 (−0.89 to 0.87) | 0.98 | 0 | 0.99 | 0.09 |
| Serum phosphorus, mg/dl | 3 | 28 | 0.29 (−0.79 to 1.37) | 0.60 | 0 | 0.75 | 0.90 |
| Serum albumin, g/dl | 3 | 28 | 0.27 (−0.29 to 0.83) | 0.35 | 0 | 0.58 | 0.22 |
| Serum intact parathyroid hormone, pg/ml | 3 | 28 | −1.47 (−35.44 to 32.51) | 0.93 | 0 | 0.67 | 0.52 |
| Risk ratio (95% CI) | |||||||
| Amputation | 7 | 52 | 0.93 (0.29–2.97) | 0.90 | 0 | 0.85 | 0.97 |
| Worsening of lesions | 4 | 28 | 0.66 (0.23–1.93) | 0.45 | 39.9 | 0.17 | 0.69 |
| Mortality | 7 | 151 | 0.89 (0.71–1.12) | 0.31 | 0 | 0.83 | 0.51 |
| Mortalitya | 7 | 151 | 0.89 (0.71–1.12) | 0.31 | 0 | 0.83 | 0.51 |
a
Subgroup analysis of cohort studies published in 2006 and thereafter (the year that the use of cinacalcet for the treatment of calciphylaxis was first reported).